• Contact

  • Newsletter

  • About us

  • Delivery options

  • Prospero Book Market Podcast

  • Cancer Biomarkers: The Urokinase Plasminogen Activator System: Molecular Mechanisms and Clinical Relevance

    Cancer Biomarkers: The Urokinase Plasminogen Activator System by Schmitt, Manfred; Foekens, John; Sweep, Fred C.G.J.;

    Molecular Mechanisms and Clinical Relevance

      • GET 5% OFF

      • The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
      • Publisher's listprice EUR 199.95
      • The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.

        82 929 Ft (78 980 Ft + 5% VAT)
      • Discount 5% (cc. 4 146 Ft off)
      • Discounted price 78 783 Ft (75 031 Ft + 5% VAT)

    82 929 Ft

    Availability

    Uncertain availability. Please turn to our customer service.

    Why don't you give exact delivery time?

    Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.

    Product details:

    • Publisher De Gruyter
    • Date of Publication 15 January 2016

    • ISBN 9783110312225
    • Binding Unidentified
    • No. of pages460 pages
    • Size 240x170 mm
    • Language English
    • Illustrations Includes a print version and an ebook
    • 0

    Categories

    Long description:

    The serine protease urokinase-type plasminogen activator, its inhibitor and its receptor are considered the most valuable prognostic cancer biomarkers relevant to predict the clinical course of cancer patients and their response to cancer therapy. They are also among the few biomarkers that have been evaluated successfully in clinical studies for their clinical utility, for the most part in early breast cancer. This work provides an overview of the molecular mechanisms and clinical outlook of this important proteolytic system.

    More